Sugi Predict

Sugi Predict / Compounds / SCHEMBL371833

SCHEMBL371833

SCHEMBL371833

COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)NCc5ccc(F)cc5)CC4)cc3)c2cc1OC

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AXL P30530 12/20 0.86
▸ MET P08581 11/20 0.86
▸ AURKB Q96GD4 4/20 0.86
▸ MERTK Q12866 3/20 0.86
▸ KDR P35968 3/20 0.86
▸ FLT1 P17948 3/20 0.86
▸ FLT3 P36888 2/20 0.86
▸ AURKA O14965 1/20 0.86
▸ RIPK2 O43353 1/20 0.86
▸ ABCB11 O95342 1/20 0.86
▸ ABL1 P00519 1/20 0.86
▸ EGFR P00533 1/20 0.86
▸ ERBB2 P04626 1/20 0.86
▸ NTRK1 P04629 1/20 0.86
▸ LCK P06239 1/20 0.86
▸ PGR P06401 1/20 0.86
▸ LYN P07948 1/20 0.86
▸ RET P07949 1/20 0.86
▸ CHRM2 P08172 1/20 0.86
▸ HCK P08631 1/20 0.86

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29693399 1.00 AXL (0.86) AXLMETAURKBMERTKKDR
Cabozantinib SCHEMBL360795 0.93 AXL (1.00) AXLMETAURKBMERTKKDR
Cabozantinib SCHEMBL29728791 0.93 AXL (1.00) AXLMETAURKBMERTKKDR
Cabozantinib SCHEMBL29351408 0.93 AXL (1.00) AXLMETAURKBMERTKKDR
Cabozantinib SCHEMBL18095042 0.92 AXL (0.98) AXLMETAURKBMERTKKDR
Cabozantinib SCHEMBL18097906 0.90 AXL (0.94) AXLMETAURKBMERTKKDR
SCHEMBL21688471 0.90 AXL (0.90) AXLMETAURKBMERTKKDR
Cabozantinib SCHEMBL18097904 0.90 AXL (0.90) AXLMETAURKBMERTKKDR
Cabozantinib SCHEMBL18095040 0.90 AXL (0.93) AXLMETAURKBMERTKKDR
SCHEMBL30692003 0.89 AXL (0.93) AXLMETAURKBMERTKKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3329918-B1 C-MET MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2022-05-25 — — EP claimed
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. 2021-08-19 — — US claimed
US-20200331860-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2020-10-22 — — US claimed
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 — — EP claimed
EP-3329918-A2 C-MET MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2018-06-06 — — EP claimed
US-20170355678-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2017-12-14 — — US claimed
EP-2409704-B1 c-Met modulators and methods of use EXELIXIS INC (US) 2017-09-20 — — EP claimed
US-20160185725-A1 c-Met Modulators and Method of Use EXELIXIS, INC. 2016-06-30 — — US claimed
US-20150376133-A1 C-Met Modulators and Methods of Use EXELIXIS, INC. 2015-12-31 — — US claimed
US-20120022065-A1 C-Met Modulators and Method of Use EXELIXIS, INC. (US) 2012-01-26 — — US claimed
EP-2409704-A2 c-Met modulators and methods of use Exelixis Inc. (US) 2012-01-25 — — EP claimed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US claimed
EP-3329918-B1 C-MET MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2022-05-25 — — EP disclosed
EP-3329918-B1 C-MET MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2022-05-25 — — EP disclosed
US-11124482-B2 C-met modulators and methods of use EXELIXIS, INC. (US) 2021-09-21 — — US disclosed
US-11124482-B2 C-met modulators and methods of use EXELIXIS, INC. (US) 2021-09-21 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed
WO-2006108059-A1 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2006-10-12 — — WO disclosed
EP-1673085-A2 C-MET MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2006-06-28 — — EP disclosed
WO-2005030140-A2 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2005-04-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331860-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET AXL 109/4885MET 3/4885AURKB 790/4885
US-20070054928-A1 c-Met modulators and methods of use FLT4, FLT1, MET AXL 109/4885MET 3/4885AURKB 790/4885
US-20120022065-A1 C-Met Modulators and Method of Use FLT4, MET, FLT1 AXL 241/4885MET 2/4885AURKB 559/4885
US-20150376133-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET AXL 109/4885MET 3/4885AURKB 790/4885
US-20170355678-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET AXL 109/4885MET 3/4885AURKB 790/4885
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE FLT4, FLT1, MET AXL 109/4885MET 3/4885AURKB 790/4885
US-20160185725-A1 c-Met Modulators and Method of Use FLT4, MET, FLT1 AXL 241/4885MET 2/4885AURKB 559/4885
US-11124482-B2 C-met modulators and methods of use FLT4, FLT1, MET AXL 109/4885MET 3/4885AURKB 790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.